Hepatic Mitochondrial Metabolism in Fatty Liver Disease in Humans

Inclusion Criteria

• •1. Participants must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
• •2. Subject must be likely to be available to complete all protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge.
• •3. Age range from 18-75 years.
• •4. No known hypersensitivity to egg, soy, or peanut protein, or to any of the substances of Intralipid 20%, or to any other substance to be administered during the study.
• •5. No severe hyperlipidemia or hemophagocytotic syndrome as judged by history and physical examination and standard laboratory tests.
• •6. No other liver disease except for SLD.
• •7. No advanced liver disease as judged by history and physical examination and standard laboratory tests.
• •8. No claustrophobia or metal implants to allow magnetic resonance studies.
• •9. No pregnancy or lactation in women.
• •10. No known or anticipated difficulties in cannulation of peripheral veins.
• •11. No history or evidence of any other clinically significant disorder, condition or disease other than those outlined above that, in the opinion of the investigator may compromise the ability of the subject to give written informed consent, would pose a risk to subject safety, or interfere with the study evaluation, procedures or completion.
• •12. No drinking problem based on AUDIT questionnaire.
• •13. No use of medications interacting with alcohol.
• •14. No history of heparin induced thrombosytopenia (HIT) or bleeding tendency.
• •15. No current use of warfarin, direct anticoagulants, or thrombocyte inhibitors.